159 related articles for article (PubMed ID: 38131226)
1. Mettl3‑mediated m
Lin X; Yang Y; Huang Y; Li E; Zhuang X; Zhang Z; Xu R; Yu X; Deng F
Mol Med Rep; 2024 Mar; 29(3):. PubMed ID: 38214327
[TBL] [Abstract][Full Text] [Related]
2. Emerging function of main RNA methylation modifications in the immune microenvironment of digestive system tumors.
Zeng Y; Yu T; Lou Z; Chen L; Pan L; Ruan B
Pathol Res Pract; 2024 Apr; 256():155268. PubMed ID: 38547773
[TBL] [Abstract][Full Text] [Related]
3. RNA methylation-related inhibitors: Biological basis and therapeutic potential for cancer therapy.
Chen H; Liu H; Zhang C; Xiao N; Li Y; Zhao X; Zhang R; Gu H; Kang Q; Wan J
Clin Transl Med; 2024 Apr; 14(4):e1644. PubMed ID: 38572667
[TBL] [Abstract][Full Text] [Related]
4. RNA m6A modifications regulate crosstalk between tumor metabolism and immunity.
Gu J; Cao H; Chen X; Zhang XD; Thorne RF; Liu X
Wiley Interdiscip Rev RNA; 2024; 15(1):e1829. PubMed ID: 38114887
[TBL] [Abstract][Full Text] [Related]
5. Single-Atom Catalysts Mediated Bioorthogonal Modulation of N
Sun M; Liu X; Liu Z; Zhang W; Li G; Ren J; Qu X
J Am Chem Soc; 2024 Mar; 146(12):8216-8227. PubMed ID: 38486429
[TBL] [Abstract][Full Text] [Related]
6. Editorial: DNA methylation, tumor microenvironment and their effects in immunotherapy and drug resistance in thoracic tumors.
Qu L; Ding S; Long Q; Zheng S; Chen ZS; Yi W
Front Immunol; 2024; 15():1357278. PubMed ID: 38288309
[No Abstract] [Full Text] [Related]
7. METTL14‑mediated RNA methylation in digestive system tumors.
Hu J; Lin H; Wang C; Su Q; Cao B
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37539726
[TBL] [Abstract][Full Text] [Related]
8. Roles of METTL3 in cancer: mechanisms and therapeutic targeting.
Zeng C; Huang W; Li Y; Weng H
J Hematol Oncol; 2020 Aug; 13(1):117. PubMed ID: 32854717
[TBL] [Abstract][Full Text] [Related]
9. Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review).
Shao C; Han Y; Huang Y; Zhang Z; Gong T; Zhang Y; Tian X; Fang M; Han X; Li M
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38131226
[TBL] [Abstract][Full Text] [Related]
10. m
Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
[TBL] [Abstract][Full Text] [Related]
11. METTL3 promotes proliferation and migration of colorectal cancer cells by increasing SNHG1 stability.
Xu Y; Bao Y; Qiu G; Ye H; He M; Wei X
Mol Med Rep; 2023 Nov; 28(5):. PubMed ID: 37772373
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
[TBL] [Abstract][Full Text] [Related]
13. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.
Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G
J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
15. m
Collignon E; Cho B; Furlan G; Fothergill-Robinson J; Martin SB; McClymont SA; Ross RL; Limbach PA; Ramalho-Santos M
Nat Cell Biol; 2023 Sep; 25(9):1279-1289. PubMed ID: 37696947
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
